Original Article
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Tasa de retención a un año de ixekizumab en pacientes con artritis psoriásica y espondiloartritis axial: datos de vida real del registro BIOBADASER
Clementina López-Medinaa,
, Lucía Otero-Varelab, Fernando Sánchez-Alonsob, Vega Jovaníc, Lorena Expósito-Pérezd, Sheila Melchor-Díaze, Yanira Pérez-Veraf, Paula Pretel-Ruizg, Javier Maneroh, Antonio Mera-Varelai, Lourdes Mateoj, Dolores Ruiz-Montesinok, José Andrés Lorenzo-Martínl, Teresa Pedraz-Penalvam, Isabel Castrejónn,o
Corresponding author
a University of Cordoba, Reina Sofia University Hospital, IMIBIC, Cordoba, Spain
b Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
c Hospital General Universitario de Alicante Dr. Balmis, ISABIAL, Alicante, Spain
d Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
e Hospital Universitario 12 de Octubre, Madrid, Spain
f Hospital Universitario de Gran Canarias Dr. Negrín, Las Palmas de Gran Canaria, Spain
g Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
h Hospital Universitario Miguel Servet, Zaragoza, Spain
i Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
j Hospital Universitario Germans Trias I Pujol, Badalona, Spain
k Hospital Universitario Virgen Macarena, Sevilla, Spain
l Hospital Universitario de Burgos, Burgos, Spain
m Hospital General Universitario de Elda Virgen de la Salud, Elda, Spain
n Gregorio Marañón University Hospital, Madrid, Spain
o Faculty of Medicine, Complutense University, Madrid, Spain
Ver másRead
455
Timeswas read the article
96
Total PDF
359
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 9 | 2 | 11 |
| 2025 11 | 308 | 73 | 381 |
| 2025 10 | 6 | 12 | 18 |
| 2025 9 | 1 | 0 | 1 |
| 2025 8 | 1 | 0 | 1 |
| 2025 7 | 1 | 1 | 2 |
| 2025 6 | 30 | 8 | 38 |
| 2025 5 | 3 | 0 | 3 |
